INCR News

InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages

InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds

InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition

Inocras Announces ASCO 2026 Online Publication: Whole-genome HRD phenotyping as a predictor of PARP inhibitor benefit in first-line maintenance high-grade serous ovarian cancer

InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow

Transaction in Own Shares

Smartly firma carta de intención para adquirir INCRMNTAL

Transaction in Own Shares

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement